{"id":"NCT01369329","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2013-06","completion":"2013-07","firstPosted":"2011-06-08","resultsPosted":"2016-12-07","lastUpdate":"2016-12-07"},"enrollment":769,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease","IBD","Colitis","Inflammatory Bowel Disease"],"interventions":[{"type":"DRUG","name":"Group 2 ustekinumab 130 mg","otherNames":[]},{"type":"DRUG","name":"Group 3: ustekinumab approximately 6 mg/kg","otherNames":[]},{"type":"DRUG","name":"Group 1: Placebo","otherNames":[]}],"arms":[{"label":"001","type":"PLACEBO_COMPARATOR"},{"label":"002","type":"EXPERIMENTAL"},{"label":"003","type":"EXPERIMENTAL"}],"summary":"This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn's disease who have either failed or could not tolerate at least one TNF-antagonist medications in the past (specifically, infliximab, adalimumab, or certolizumab pegol).","primaryOutcome":{"measure":"Number of Participants With Clinical Response at Week 6","timeFrame":"Baseline and Week 6","effectByArm":[{"arm":"Placebo","deltaMin":53,"sd":null},{"arm":"Ustekinumab 130 Milligram (mg)","deltaMin":84,"sd":null},{"arm":"Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg)","deltaMin":84,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.002"},{"comp":"OG000 vs OG002","p":"0.003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":175,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","France","Germany","Hungary","Iceland","Ireland","Israel","Japan","Netherlands","New Zealand","Poland","Serbia","South Africa","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["39996607","38310565","37391056","37368103","36150926","35435862","34077627","32964215","31279870","30739254","29909019","29409871","29142515","27959607"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":254},"commonTop":["Arthralgia","Headache","Nausea","Pyrexia","Abdominal Pain"]}}